Balancer, a pioneering DeFi automated market maker, is proposing an orderly shutdown of its protocol. The plan includes pausing pools by October 2026, stopping new development, and gradually winding down operations with a budget to maintain minimal infrastructure until mid-2027. At least $9 million from the treasury will be distributed to BAL token holders who burn their tokens starting May 2027, with multiple redemption rounds through mid-2028. This move follows declining revenue and a major 2025 exploit, marking the end of Balancer's efforts to sustain growth.
Balancer's proposed orderly winddown and treasury distribution to BAL holders provide context for the current market environment. For readers following major cryptocurrencies on Pluang, as of Sep 15, 2026 17:31 WIB, 13 of 50 major cryptocurrencies rose while 36 fell. BAL was priced at Rp16.297 with a 1-day change of +11.14%, EOS at Rp12.649 with +8.13%, and COTI at Rp306 with +7.77%.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
